Lurasidone for the Treatment of Schizophrenia: Design, Development, and Place in Therapy

作者：Itaru Miura, Sho Horikoshi, Mizue Ichinose, Yuhei Suzuki, Kenya Watanabe · 发表于：Drug Design Development and Therapy · 年份：2023 · DOI：10.2147/dddt.s366769 · 被引用次数：27 · 研究领域：Schizophrenia research and treatment、Bipolar Disorder and Treatment、Receptor Mechanisms and Signaling

Abstract: This review aims to provide a comprehensive overview of the current literature on the drug design, development, and therapy of lurasidone for the treatment of schizophrenia. Lurasidone has antagonistic effects on the dopamine D 2 , 5-hydroxytryptamine (5-HT) 2A , and 5-HT 7 receptors and a partial agonistic effect on the 5-HT 1A receptor with low affinities for muscarinic M 1 , histamine H 1 , and a 1 adrenergic receptors. The receptor-binding profile of lurasidone is thought to be associated with fewer side effects such as anticholinergic effects, lipid abnormalities, hyperglycemia, and weight gain. Behavioral pharmacological studies have demonstrated that lurasidone exerts anxiolytic and antidepressive effects and improves cognitive function, which are associated with the modulation of 5-HT 7 and 5-HT 1A receptors. Literature search using PubMed was performed to find published studies of randomized controlled trials and recent meta-analyses regarding efficacy and safety, particularly metabolic side effects of lurasidone in schizophrenia. In short-term studies, the results of randomized placebo-controlled trials and meta-analyses have suggested that lurasidone was superior to placebo in improving total psychopathology, positive symptoms, negative symptoms, and general psychopathology in patients with acute schizophrenia. Regarding safety, lurasidone had minimal metabolic side effects, and was identified as one of the drugs with the most benign profiles for metaboli...